Erythropoiesis-Stimulating Agents, Insulin, and Human Growth Hormone (Physician Perspectives) | Biosimilars Advisory Service | US/EU5/Japan | 2014
Nephrologists and endocrinologists in Europe have had the opportunity to use biosimilar erythropoiesis-stimulating agents (ESAs) and human growth hormone (hGH), respectively, for several years, but the uptake of these biosimilars has varied from country to country, as well as by drug class and manufacturer. New biosimilars (e.g., biosimilar insulin glargine in Europe and biosimilar epoetin alfa in the United States) are nearing the market that could face similarly muted adoption, or be embraced with greater enthusiasm than their predecessors. To understand why the penetration of biosimilars is so variable, we surveyed endocrinologists and nephrologists about their concerns with current biosimilars, the drivers and barriers to uptake, and their willingness to use biosimilars in future. By consolidating our findings from French, German, and U.S. physicians, we are able to draw meaningful conclusions about adoption rates of current and future biosimilars and provide granular brand and biosimilar market forecasts for the United States, Europe, and Japan.
